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Mathews et al. propose an ambitious pathway for validation of
digital health and mention that a pilot study and detailed
corresponding framework are forthcoming.1 While we are gen-
erally supportive of initiatives to improve the usefulness and value
that digital health can offer, we have some considerations and
suggestions. Firstly, it needs to be further clariﬁed which types of
interventions the digital health scorecard will deal with as a ‘one-
size ﬁts all’ approach for validation is unlikely to succeed. As
Mathews et al. describe, digital health includes a wide range of
scientiﬁc concepts, technologies, functions, and users.1 For
example, if we only consider health apps, not even one initiative
will be able to provide a framework for scoring all the 300,000+
and the 200+ mobile health apps, which are added daily cited by
the authors.2 Most of these apps do not fall under medical device
regulation or even have a ‘medical purpose’ but are aimed at
improving wellbeing and ﬁtness. The gatekeeper in this aspect are
the app stores and, for example, Apple’s App store has created a
checklist of items that health apps should adhere to.3 Collaborat-
ing with app stores is one way to ensure that published health
apps at least adhere to basic quality standards.
Secondly, deﬁning the scope of a digital health scorecard will
aid in proving its value before considerable amounts of efforts
and resources are being spent. There are some similarities
between the emergence of the internet as a popular source of
health information two decades ago and digital health apps over
the past years. The Internet has been a source for medical
disinformation and misinformation, which can be argued to have
reduced the credibility of science and medicine, similarly for
many health apps.4 Previously, many called for and developed
quality schemes of health information websites, as is now also the
case for health apps. There are intrinsic difﬁculties in scoring the
quality of online health information and such schemes need to
demonstrate their beneﬁt to the public and patients,5 which we
think might also the case for health apps and other digital health
interventions.6 Identifying and quantifying risks is more challen-
ging in the science of beneﬁt-risk assessment as risks depend on
the hard to predict consequences of interactions of interventions
with other variables in real-life situations. Assessment of the
safety of new digital health technologies is not well established
and should be undertaken more rigorously. This would help
health technology assessment organisations and regulatory
bodies to measure the efﬁcacy and safety of new digital health
technologies such as apps in robust and reliable ways, while not
stiﬂing useful innovation.
Thirdly, as the authors outline in their review paper, ‘usability
is arguably among the most important considerations with
patient-oriented mobile and digital-based solutions’. Figure 2
outlines the traditional product lifecycle with the proposed
digital health scorecard added and starts with ‘needs’ in the
developer section. We suggest that input from user and subject
experts is crucial to determine these ‘needs’ from the start of
the process.7
Fourthly, to establish ‘a multi-stakeholder approach that
objectively and rigorously evaluates solutions’ as the authors
describe, lessons from similar initiatives in other countries should
be learned from. Previous multi-stakeholder initiatives to reach
consensus on validation of digital health have not reached their
initial aims. For example, the European Commission established a
working group of different stakeholders to develop mHealth
assessment guidelines. After 2 years of work, it came to the
conclusion that ‘no consensus was reached among the repre-
sented constituencies on a set of guidelines.8 This work is based
on the guidance from different European countries, including the
UK health apps library that is mentioned in the review article, as
well as other initiatives such as the French Haute Autorité de Santé
(HAS) good practice guidelines. These initiatives differ substan-
tially and providing consensus has proved to be the main
challenge.4
Fifthly, Mathews et al. acknowledge complexity in this area and
that the digital health scorecard would be an approach that evolves
over time.1 As far as we are aware in most digital health evaluation
initiatives no input has been sought from countries outside the
OECD. Digital health solutions have considerable value to low- and
middle-income countries too as smartphones and other digital tools
are increasingly being adopted in these settings. The views of
stakeholders in these settings will need to be considered too to
provide contextual information that will be crucial for the
development and evaluation of appropriate digital health tools.9
We think that a digital health scorecard is an ambitious but
potentially useful initiative. To optimise its chances of succeeding,
it would be helpful to clarify with which digital health interven-
tions it will deal with, in which settings and with which purposes.
Different approaches will need to be used to develop and evaluate
the increasing number of different digital health interventions.
Also, we suggest that before pursuing a pathway for validation, its
need and value should be proven because multi-stakeholder
approaches that aimed to reach consensus on digital health
validation have shown to be challenging, time- and resource-
consuming in the past.
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